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Abstract
Background: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disease that afects 
approximately one in 500 people. HCM is a recognized genetic disorder most often caused by mutations involv-
ing myosin-binding protein C (MYBPC3) and β-myosin heavy chain (MYH7) which are responsible for approximately 
three-quarters of the identifed mutations. 
Methods: As a part of the international multidisciplinary SILICOFCM project (www.silicofcm.eu) the present study 
evaluated the association between underlying genetic mutations and clinical phenotype in patients with HCM. Only 
patients with confrmed single pathogenic mutations in either MYBPC3 or MYH7 genes were included in the study 
and divided into two groups accordingly. The MYBPC3 group was comprised of 48 patients (76%), while the MYH7 
group included 15 patients (24%). Each patient underwent clinical examination and echocardiography. 
Results: The most prevalent symptom in patients with MYBPC3 was dyspnea (44%), whereas in patients with MYH7 
it was palpitations (33%). The MYBPC3 group had a signifcantly higher number of patients with a positive family his-
tory of HCM (46% vs. 7%; p=0.014). There was a numerically higher prevalence of atrial fbrillation in the MYH7 group 
(60% vs. 35%, p=0.085). Laboratory analyses revealed normal levels of creatinine (85.5±18.3 vs. 81.3±16.4 µmol/l; 
p=0.487) and blood urea nitrogen (10.2±15.6 vs. 6.9±3.9 mmol/l; p=0.472) which were similar in both groups. The 
systolic anterior motion presence was signifcantly more frequent in patients carrying MYH7 mutation (33% vs. 10%; 
p=0.025), as well as mitral leafet abnormalities (40% vs. 19%; p=0.039). Calcifcations of mitral annulus were regis-
tered only in MYH7 patients (20% vs. 0%; p=0.001). The diference in diastolic function, i.e. E/e′ ratio between the two 
groups was also noted (MYBPC3 8.8±3.3, MYH7 13.9±6.9, p=0.079). 
Conclusions: Major fndings of the present study corroborate the notion that MYH7 gene mutation patients are 
presented with more pronounced disease severity than those with MYBPC3. 
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Hypertrophic cardiomyopathy (HCM) is the most fre-
quent inherited disease of the myocardium, with a preva-
lence of approximately 0.2% [1, 2]. Despite the signifcant 
developments in diagnostic tools and genetic tests, the 
diagnosis of HCM is often delayed [2].
HCM is characterized by left ventricular (LV) hyper-
trophy without dilatation, in the absence of any other
cardiac, systemic, metabolic, or syndromic disease that
could explain myocardial hypertrophy [2–5]. Clinical
presentation of HCM varies from completely asympto-
matic with normal life expectancy, to typical symptoms
like chest pain, shortness of breath, heart failure, pal-
pitations, syncope, and in the worst case even sudden
cardiac death [2, 6]. Complications of non-obstructive
HCM include advanced myocardial fbrosis, microvas-
cular ischemia, and deterioration of cardiac function
[7].
HCM is a recognized genetic disorder transmitted in 
an autosomal dominant fashion, caused by a single muta-
tion in one of the sarcomeric protein genes, which can be 
present in either thick- or thin-flament genes [8, 9]. Te
two most common mutations involving thick flament 
are myosin-binding protein C (MYBPC3) and β-myosin 
heavy chain (MYH7) gene mutations, which are respon-
sible for approximately three-quarters of the identifed 
mutations in HCM patients [9, 10]. Aside from these 
two, a few other less frequent gene mutations (e.g. tro-
ponin I type 3 [TNNI3], troponin T type 2 [TNNT2], 
α-tropomyosin [TPM1], α-actin [ACTC]) are possible 
causes of HCM as well and are therefore also included 
in the routine HCM genetic testing [11]. Technologi-
cal progress has made it possible to identify new genes 
associated with HCM—numerous other genes that do 
not encode sarcomere proteins but rather genes encod-
ing the synthesis of Z-disk proteins and proteins involved 
in the calcium signaling pathway. With the introduction 
and implementation of the next-generation sequencing 
solutions, the identifcation of nearly 50 gene mutations 
associated with some form of HCM throughout literature 
has become possible [12].
Regardless of the mutation type, the same pathophysi-
ology mechanisms are responsible for the development 
of typical HCM phenotype and disease progression. 
Disrupted sarcomere properties due to the mutations 
cause impaired relaxation and lead to diastolic dysfunc-
tion, which is followed by hyperdynamic contractility and 
hypertrophy of the LV in the later course [9, 11].
Due to variable penetrance and expressivity, the phe-
notypic characteristics of HCM are multifaceted and 
may be infuenced by other factors beyond single path-
ogenic mutations [13]. In addition to LV hypertrophy, 
phenotypic HCM expression also includes myocardial 
hypercontractivity, myofbril disorganization, fbrosis, 
as well as the presence of mild myocardial infamma-
tion. Although the clinical phenotype can partially difer 
depending on the afected gene, no distinctive correla-
tion between disease severity and specifc genes has been 
established. Moreover, clinical features such as disease 
penetration, hypertrophy severity, and patient progno-
sis are known to vary depending on diferent mutations 
within the same gene [11].
Te precise link between determined underlying gene 
mutation and the clinical course remains elusive in this 
heterogeneous condition. Te motivation to compile this 
HCM patient registry was to try to defne what patient 
features are more prevalent with specifc gene mutations 
and to establish whether the level of disease expression 
might be linked to one of the two most common muta-
tions responsible for HCM. Te goal was to reveal and 
distinguish subtle diferences that may exist in clinical 
presentation and, more importantly, in heart structure 
and function recorded by cardiac imaging (i.e. echo-
cardiography) between diferent gene mutations, thus 
providing essential information for the computational 
model development. Moreover, data from this study 
will also complement the clinical trial (NCT03832660 at 
clinicaltrials.gov) evaluating the efects of pharmacologi-
cal (sacubitril/valsartan) versus lifestyle intervention in 
HCM patients [14], also a fundamental part of the SILI-
COFCM project. 
Methods 
As a part of the international multidisciplinary SILI-
COFCM project (www.silicofcm.eu) developing a com-
putational platform for in silico clinical trials of familial 
cardiomyopathies, the present study evaluated the asso-
ciation between genetic mutations and clinical phe-
notype in patients with HCM. Te study protocol was 
approved by the UK National Health Service Health 
Research Authority North East—Tyne & Wear South 
Research Ethics Committee with the reference number 
18/NE/0318 and was adopted by the Institutional Review 
Board of each participating center. All patients provided 
written informed consent and all procedures were con-
ducted following the Declaration of Helsinki. 
Study design 
Participating centers included patients with diagnoses of 
HCM who were identifed in the period from June 2018 
to February 2019.
Te diagnosis of HCM was defned according to the 
European Society of Cardiology guidelines i.e. maximal 
LV wall thickness of ≥15 mm on echocardiography, in 
the absence of any other cardiac or systemic disease that 
would be capable of producing myocardial hypertrophy, 









      
  
such as afterload abnormalities like aortic valve steno-
sis or arterial hypertension [5]. Of the total of 74 HCM 
patients, 11 were excluded because of the relatively small 
number of other gene mutations (TNNI3—5 patients, 
TNNT2—2 patients, TPM1—1 patient, myosin heavy 
chain 6—1 patient, myosin light chain 2—1 patient, lamin 
A/C—1 patient) might have biased the overall study anal-
ysis. In the fnal analysis, the study included a total of 63 
adult patients with a confrmed diagnosis of HCM.
We excluded patients with signifcant atheroscle-
rotic coronary artery disease (>50% stenosis in a major 
artery), patients with prior cardiac surgery (including 
septal myectomy), alcohol septal ablation, major LV out-
fow obstruction with pressure gradient >50 mmHg, and 
chronic renal failure (<30 ml/min/1.73 m2). 
Genetic testing 
Genetic testing was performed from peripheral blood 
samples acquired by phlebotomy with the utilization of 
the QIAamp DNA Blood BioRobot MDx kit (QIAGEN 
GmbH, Hilden, Germany). Polymerase chain reaction 
with primers was used for the amplifcation of candidate 
exons. 
Blood samples were analyzed for the presence of the 
8 most common mutations, which represent the basis 
of the commonly available genetic tests for HCM. Tese 
mutations include the protein-coding exons responsi-
ble for encoding myosin-binding protein C (MYBPC3), 
thick-flament proteins (β-myosin heavy chain [MYH7] 
and the regulatory and essential light chains [MYL2 and 
MYL3]), and thin-flament proteins (troponin T type 2 
[TNNT2], troponin I type 3 [TNNI3], α-tropomyosin 
[TPM1], and α-actin [ACTC]).
Only patients with confrmed single pathogenic muta-
tions in either MYBPC3 or MYH7 genes were included 
in the study. Based on the identifed gene mutation the 
patients were divided into two groups. Te MYBPC3 
group was comprised of 48 patients (76%), while the 
MYH7 group included 15 patients (24%). 
Electrocardiogram and ECG Holter monitoring 
Te ECG was performed using a standard 12-lead-
electrocardiogram in a supine position. To identify spo-
radic arrhythmia, all participants were asked to wear 
an ECG-Holter monitor for 24 h and to keep a diary of 
activities and symptoms. 
Echocardiography 
Transthoracic echocardiography was performed in all 
patients. Images were obtained using regular parasternal 
and apical views. All the parameters were calculated and 
indexed for body surface area (BSA). 
LV wall thickness and chamber dimensions were meas-
ured using the parasternal long-axis view [14, 15]. Te
Devereux formula [16] was used to calculate LV myocar-
dial mass. 
LV geometry was assessed by the relative wall thickness 
which is calculated as two times the LV posterior wall 
thickness divided by LV end-diastolic diameter.
LV systolic and diastolic volumes were measured with 
Simpson’s modifed biplane method using apical 4-cham-
ber and 2-chamber views, and LV systolic function was 
expressed through the ejection fraction [15].
For diastolic function assessment, an apical 4-chamber 
view was used [17]. Blood fow through the mitral valve 
was measured by pulsed-wave Doppler between the tips 
of mitral leafets and the peak modal velocity in early 
diastole (E) was determined. Velocities of basal regions at 
lateral and septal mitral annulus were recorded using tis-
sue Doppler imaging and then their average ratio (e′) was 
computed.
Te flling pressure of the LV was expressed through 
the E/e′ ratio, which is the most accurate indicator of 
diastolic function according to the literature [18]. 
Statistical analysis 
Continuous variables are expressed as mean val-
ues± standard deviation and categorical variables are 
presented as absolute numbers and percentages. Quanti-
tative data distribution was assessed using the Kolmogo-
rov–Smirnov test. Mean values of continuous variables 
were compared using the independent samples t-test or 
Mann–Whitney U test, whereas categorical variables 
were compared using the chi-square test. Statistical sig-
nifcance for all tests was set at the p value of <0.05. All 
the analyses were done in SPSS version 20.0. 
Results 
Te mean age of HCM patients regardless of genetic 
mutation was 51.1±14.2  years and most of them were 
male 48 (76%). Tey were slightly overweight accord-
ing to their mean BMI of 26.4±4.4 kg/m2. One-third of 
patients (36%) had a positive family history for HCM.
Diferences in terms of patient profle depending on 
genetic mutation are shown in Table 1. 
Tere was no signifcant diference between patients 
carrying the MYBPC3 and MYH7 mutations regarding 
age (49.8±14.3 vs. 55.1±13.3 years, p=0.211) and gen-
der distribution (21% vs. 33% females, p=0.321).
Te most prevalent symptom in patients with MYBPC3 
was dyspnea (44%), whereas in patients with MYH7 it 
was palpitations (33%). Other less frequently reported 
symptoms included fatigue, chest pain, and syncope, with 
similar distribution among the groups. 










       
     
   




       
   
    




   
  
      





       
       
       
       
       
       
       
       
       
       
Table 1 General characteristics of patients with MYBPC3 and MYH7 gene mutation 
Overall MYBPC3 MYH7 p value 
Age (years) 51.1±14.2 49.8±14.3 55.1±13.3 0.211 
Females, n (%) 15 (23.8%) 10 (20.8%) 5 (33.3%) 0.321 
BMI (kg/m2) 26.4±4.4 26.1±4.6 27.8±3.1 0.260 
Fatigue, n (%) 9 (14.3%) 7 (14.6%) 2 (13.3%) 0.881 
Dyspnea, n (%) 25 (39.7%) 21 (43.7%) 4 (26.7%) 0.238 
Chest pain, n (%) 6 (9.5%) 4 (8.3%) 2 (13.3%) 0.565 
Palpitations, n (%) 13 (20.6%) 8 (16.7%) 5 (33.3%) 0.177 
Syncope, n (%) 10 (15.9%) 9 (18.7%) 1 (6.6%) 0.264 
Family history of HCM, n (%) 23 (36.5%) 22 (45.8%) 1 (6.6%) 0.014* 
Comorbidities 
Diabetes mellitus, n (%) 3 (4.8%) 3 (6.2%) – – 
Chronic obstructive pulmonary disease, 2 (3.2%) 2 (4.2%) – – 
n (%) 
Thyroid dysfunction, n (%) 8 (12.7%) 7 (14.6%) 1 (6.7%) 0.422 
Anemia, n (%) 1 (1.6%) 1 (2.1%) – – 
Laboratory analyses 
Glucose (mmol/l) 5.6±1.2 5.8±1.3 5.0±0.6 0.071 
Creatinine (µmol/l) 84.4±17.7 85.5±18.3 81.3±16.4 0.487 
Blood urea nitrogen (mmol/l) 9.0±12.7 10.2±15.6 6.9±3.9 0.472 
ALT (U/l) 30.1±15.7 31.8±17.0 25.0±10.4 0.268 
Total protein (g/l) 69.1±8.4 69.3±7.2 68.6±11.1 0.853 
Albumin (g/l) 44.0±6.8 44.1±6.4 43.9±8.0 0.948 
Sodium (mmol/l) 140.3±2.1 140.4±2.1 140.2±2.3 0.868 
Potassium (mmol/l) 4.5±0.4 4.5±0.3 4.6±0.5 0.531 
Calcium (mmol/l) 2.3±0.1 2.3±0.1 2.3±0.2 0.689 
NT-proBNP (ng/l) 1328.3±1420.2 1304.5±1457.5 1757.2±1335.2 0.766 
ALT alanine transaminase, BMI body mass index, HCM hypertrophic cardiomyopathy, NT-proBNP N-terminal pro-brain natriuretic peptide 
Interestingly, the MYBPC3 group had a signifcantly 
higher number of patients with a positive family history 
of HCM (46% vs. 7%; p=0.014).
Te most frequently found comorbidity was thyroid 
gland dysfunction, which was present in 8 patients (13%) 
in total, without signifcant diference between MYBPC3 
and MYH7 groups (15% vs. 7%; p=0.422). No signifcant 
diference between the MYBPC3 and MYH7 patients was 
observed in other comorbidities as well: diabetes mel-
litus (6% vs. 0%; p=0.321), chronic obstructive pulmo-
nary disease (4% vs. 0%; p=0.422), anemia (2% vs. 0%; 
p=0.573).
Te mean heart rate was similar between MYBPC3 
and MYH7 patients (64.6±11.8 vs. 67.8±20.4  bpm; 
p=0.546). However, there was a numerically higher 
prevalence of atrial fbrillation in the MYH7 group (60% 
vs. 35%, p=0.085).
Blood laboratory analyses indicating renal and liver 
function, as well as blood glucose and electrolytes, 
showed levels within the reference range, without difer-
ences between MYBPC3 and MYH7 patients (Table  1). 
Levels of N-terminal pro-brain natriuretic peptide (NT-
proBNP) were elevated in all patients, but without difer-
ence among groups.
Echocardiography fndings are presented in Table  2
and Fig.  1. Tere was no diference in the posterolat-
eral wall (10.6± 2.1 vs. 10.8± 1.7  mm, p= 0.776) and
interventricular septum (21.5± 7.0 vs. 21.6± 7.9  mm,
p= 0.982) thickness between MYBPC3 and MYH7
patients. Left atrial volume was 14% lower (p= 0.518)
and left ventricular end-diastolic volume was 19%
higher (p= 0.560) in MYBPC3. Left ventricular end-
systolic volume was similar between MYBPC3 and
MYH7 (52.6± 37.4 vs. 44.0± 19.0  ml; p= 0.700) as
was left ventricular ejection fraction (55.6± 8.2 vs.
54.1± 6.3, p= 0.594) and tricuspid annular plane sys-
tolic excursion (TAPSE) (21.0± 4.4 vs. 22.5± 6.0 mm,
p= 0.363).
Importantly, the systolic anterior motion was signif-
cantly higher in patients carrying MYH7 mutation (33%
vs. 10%; p= 0.025), as well as mitral leafet abnormali-
ties (40% vs. 19%; p= 0.039). Calcifcations of mitral




       
 
  
      
      
      
      
      
      
      
      
      
      
      
      
Table 2 Echocardiography fndings in patients with MYBPC3 and MYH7 gene mutation 
Overall MYBPC3 MYH7 p value 
PLW thickness (mm) 10.6±2.0 10.6±2.1 10.8±1.7 0.776 
IVS thickness (mm) 21.5±7.1 21.5±7.0 21.6±7.9 0.982 
LA volume (ml) 115.6±56 111.7±83.9 130.3±87.2 0.518 
LV end-diastolic volume (ml) 108.9±49.7 110.8±52.2 92.7±7.0 0.560 
LV end-systolic volume (ml) 51.6±35.6 52.6±37.4 44.0±19.0 0.700 
LV ejection fraction (%) 55.3±7.8 55.6±8.2 54.1±6.3 0.594 
LV mass (g) 301.4±114.0 306.0±115.2 261.0±115.4 0.527 
LV mass index (g/m2) 155.9±52.3 159.0±53.1 129.5±43.1 0.364 
Relative wall thickness 0.43±0.10 0.44±0.10 0.34±0.02 0.103 
LV outfow pressure gradient (mmHg) 8.2±11.1 6.0±2.5 16.1±22.7 0.252 
E/e′ ratio 9.7±4.5 8.8±3.3 13.9±6.9 0.079* 
TAPSE (mm) 21.4±4.8 21.0±4.4 22.5±6.0 0.363 
Systolic anterior motion, n (%) 10 (15.9%) 5 (10.4%) 5 (33.3%) 0.025* 
Papillary muscle abnormalities, n (%) 4 (6.3%) 4 (8.3%) – 0.261 
Mitral leafet abnormalities, n (%) 15 (23.8%) 9 (18.8%) 6 (40.0%) 0.039* 
Calcifcation of mitral annulus, n (%) 3 (4.8%) – 3 (20.0%) 0.001* 
PLW posterolateral wall, IVS interventricular septum, LA left atrium, LV left ventricle, E/e′ LV flling pressure, TAPSE tricuspid annular plane systolic excursion 
annulus were registered only in MYH7 patients (20%
vs. 0%; p= 0.001).
An interesting fnding is the diference of E/e′ ratio— 
a marker of LV flling pressure—between the groups
(MYBPC3 8.8± 3.3, MYH7 13.9± 6.9, p= 0.079).
Although the level of signifcance is slightly beyond the
threshold, the diference is indicative. 
Discussion 
Te genetic basis of HCM is more complex than previ-
ously thought: known genetic mutations are responsible 
for about half of the cases, while the remaining causes 
are unknown. Since variants have not been found to 
explain the presence of the disease in many patients, 
there are certainly other, yet unidentifed genes. Tere is 
an emphasized need to discover additional genetic, epi-
genetic, and environmental causes that would explain 
the high proportion of cases of unknown etiology. For 
many newly reported genes, the lack of strong evidence 
to support a causal role in HCM creates uncertainty in 
the interpretation of the results. One of the major roles of 
genetic testing for HCM patients is better clinical surveil-
lance of asymptomatic family members.
Tis study analyzed the genetic determinacy of vari-
ous clinical phenotype parameters among patients with 
HCM. Only carriers of a single gene mutation, either 
MYBPC3 or MYH7 were included. Studies that per-
formed genetic screening in large cohorts of patients 
with a confrmed clinical diagnosis of HCM managed 
to detect a pathogenic mutation in about 40–50% of 
patients [13, 15], suggesting that as much as half of the 
HCM diagnosed patients do not have known sarcomeric 
gene mutations.
Te MYBPC3 and MYH7 mutations are the two most 
common mutations among HCM patients with identifed 
sarcomeric gene mutations. A recent meta-analysis on 
7675 HCM patients including a total of 51 studies per-
formed by Sedaghat-Hamedani et al. [16] found that the 
prevalence of MYBPC3 and MYH7 gene mutations were 
20% and 14%, respectively, while all the other mutations 
had a prevalence below 2%.
HCM is a disease of a younger age, as it is often frst 
diagnosed before the age of 40 [15, 17]. In our study, 
patients’ mean age was 50 for MYBPC3 and 55 for MYH7 
mutations, with no signifcant diference among groups. 
Tis contrasts with previous fndings, which suggest ear-
lier onset and diagnosis of the disease for MYH7 muta-
tion [16, 18]. Patients in our study were predominantly 
male, which is consistent with gender distribution across 
literature, where about two-thirds of HCM patients are 
male [13, 19, 20].
Olivotto et  al. [21] in their multicenter study from 
2005, examined diferences in HCM presentation among 
genders in a population of 969 patients. Although most 
patients were male (59%), mortality rates did not difer 
among genders. Te authors also pointed out that female 
patients with HCM although more symptomatic, were 
under-represented and older. Females were more sus-
ceptible to advanced heart failure development, mostly 
due to LV outfow obstruction. Results from a more 
recent study from Jang et al. [22] conducted on 202 HCM 
patients without LV outfow obstruction are in-line with 














    Fig. 1 Echocardiography parameters in MYBPC3 and MYH7 patients (no signifcant diference was observed in the presented parameters, p>0.05) 
(IVS interventricular septum, PLW posterolateral wall, LA left atrium, LVEDV left ventricle end-diastolic volume, LVESV left ventricle end-systolic 
volume, LVEF left ventricle ejection fraction) 
previously mentioned. Jang et al. concluded that females 
had a higher incidence of heart failure, as well as a greater 
risk of hospitalization and cardiovascular-related mortal-
ity. A higher risk of heart failure in female patients was 
attributed to the diferences in LA and LV morphology 
and diastolic function between the genders.
Patients with MYBPC3 mutation in our study had
a notable number (46%) of relatives with a confrmed
HCM diagnosis. Across the literature, various rates of
positive family history ranging from 25 to 70% have
been reported [18, 19]. However, the reliability of these
numbers should be taken with reserve, because fam-
ily screening in patients with HCM has still not been
fully implemented, despite the clear recommendations
for a detailed follow-up of all adult frst-degree relatives
[5, 23]. New evidence suggests that screening should
be performed even earlier in child age, especially in
families with MYBPC3 and MYH7 mutations [24]. 
Moreover, the diagnosis in relatives is often established
solely on phenotypic expression (i.e. imaging meth-
ods like echocardiography and cardiac magnetic reso-
nance), without proper genetic testing. Even in the case
of performed genetic analysis, currently available meth-
ods still fail to identify more than half of patients with
HCM [25].
Several studies have attempted to diferentiate between 
disease severity, progression, and phenotype-based on 
specifc mutation subclasses, but there is currently no 
consensus as to whether a specifc phenotype or prog-
nosis can be predicted from an MYBPC3 mutation [26].
Mutation of the MYH7 gene is associated with an earlier 
onset of symptoms, more pronounced hypertrophy, and 
poor prognosis [27]. Te Arg453Cys mutation of MYH7 
is associated with a high incidence of terminal heart 

















   
 
    
failure and premature death [28]. Several studies have 
found a correlation between fve mutations (four in the 
MYH7 gene and one in the gene encoding cardiac tro-
ponin T) and high incidences of advanced cardiac death, 
however, these associations were not consistent with the 
results of other studies [29].
Te study by Olivotto et  al. [30] assessed the occur-
rence of atrial fbrillation and outcome in 480 consecu-
tive HCM patients (age at diagnosis, 45±20 years; 61% 
male) during a follow-up period of 9.1±6.4  years. In 
their cohort, atrial fbrillation was documented in 107 
patients, with a prevalence of 22%. Te authors con-
cluded that atrial fbrillation is associated with substantial 
risk for heart failure-related mortality, stroke, and severe 
functional disability, particularly in patients with outfow 
obstruction, those ≤50 years of age, or those developing 
chronic atrial fbrillation. 
Atrial fbrillation tended to be more prevalent in the 
MYH7 group in our study. Tis fnding is consistent with 
previous studies [17, 31], which reported a higher inci-
dence of atrial fbrillation in patients with MYH7 muta-
tion in comparison to other HCM patients. Since the 
development of atrial fbrillation was associated with 
risk factors such as LA enlargement, LV wall thickness, 
and LV outfow tract obstruction, these results suggest 
that patients with MYH7 mutation present with a more 
severe clinical phenotype. However, a prospective study 
on 237 HCM patients with a mean follow-up period of 
14±10 years found no statistically signifcant diference 
in atrial fbrillation between patients with MYBPC3 and 
MYH7 mutations, with an incidence of 31% and 37%, 
respectively [32].
Detailed analysis of echocardiography parameters 
between the MYBPC3 and MYH7 groups in the present 
study revealed a somewhat similar phenotype expression 
with minor diferences between the groups, although 
with slightly more severe disease presentation in the 
MYH7 group. Most importantly, LV wall hypertrophy 
was equally expressed in both groups at the posterolat-
eral wall and interventricular septum. Previous studies 
on larger groups of HCM patients that analyzed myocar-
dial wall thickness measured by both echocardiography 
[16–18, 33] and cardiac magnetic resonance [20] also 
discovered no signifcant diferences regarding LV wall 
thickness between MYBPC3 and MYH7 patients. Te 
somewhat counterintuitive fnding came from the Flor-
ence group [34], stating that LV mass index was normal 
in about 20% of patients with defnite HCM phenotype 
and that increased LV mass alone should not be the 
parameter for establishing the clinical diagnosis of HCM. 
Te LV mass correlated weakly with maximal wall thick-
ness and proved more sensitive in predicting outcomes. 
Heart systolic function measured through ejection frac-
tion for LV and TAPSE for right ventricle were preserved
in all study patients, with no diferences between the
groups. Tis is consistent with previous fndings and the
current standpoint that HCM generally does not lead to
systolic function deterioration. Te symptoms and clinical
severity are dominantly determined by the combination of
diastolic dysfunction, mitral apparatus abnormalities, and
LV outfow tract obstruction [35, 36]. A recent study by
Miller et al. [37] established that patients with pathogenic,
likely pathogenic or rare MYH7 variants had higher LV
ejection fraction than those with MYBPC3 variants (68.8
vs. 59.1, p<0.001) and higher right ventricle ejection frac-
tion (67.3 vs. 60.8, p=0.018). Additionally, patients with
MYBPC3 variants were more likely to have LV ejection
fraction<55% (29.7% vs. 4.9%, p=0.005).
A very interesting paper from Maron et  al. [38]
explored mitral valve abnormalities in HCM patients 
using cardiovascular magnetic resonance imaging. Mitral 
valve morphology was observed and compared between 
172 patients with HCM and 172 controls without evi-
dence of cardiovascular disease. After careful characteri-
zation, they concluded that mitral valve abnormalities 
(i.e. leafet elongation) independently contribute to the 
severity of HCM presentation, thus expanding the area 
undesirable efects of HCM genes from solely sarcomere 
mutations to valvular structures as well. We wanted to 
further classify mitral valve abnormalities depending 
on the genetic basis. In this regard, the MYH7 group in 
our study had a signifcantly higher number of mitral 
leafet abnormalities, mitral annulus calcifcations, and 
the most important higher number of systolic anterior 
motion, contributing to the worse phenotype expression 
of MYH7 versus MYBPC3 gene mutations. Te study 
of Groarke et  al. [39] observed an increased number of 
mitral valve abnormalities in patients with sarcomeric 
gene mutations, however, they did not analyze the difer-
ence among the particular gene mutations. Waldmuller 
et al. [15] on the other hand, reported a more severe level 
of mitral regurgitation in patients with MYH7 mutation 
than in patients with MYBPC3 mutation.
Diagnosis of hereditary cardiac disorders based on 
genetic information is particularly challenging because of 
the high genetic heterogeneity and overlapping and vari-
able nature of these clinical presentations. Te clinical 
presentation of HCM is infuenced by age, lifestyle, and 
presence of hypertension, among other factors. Although 
there is still no consensus on the exact impact of gender 
on HCM presentation and progression, gender infuence 
is thought to exist and that diferences in gene expression 
and hormonal diferences afect the symptoms and clini-
cal outcomes of HCM. 
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Our study was able to demonstrate the subtle but clini-
cally important diference between patients with difer-
ent genetic profles. Te clinical implications that may 
arise from these fndings point to the fact that structural 
abnormalities are more prevalent in MYH7 gene muta-
tion. Patients with MYH7 mutation would probably ben-
eft from more intense imaging surveillance that should 
start at a younger age as they are likely to develop mitral 
valve dysfunction and LVOT obstruction. Concern-
ing diastolic dysfunction, it is reasonable to assume that 
patients with MYH7 gene mutation would beneft from 
earlier commencement and more aggressive medical 
treatment. Given the clinical profle, MYH7 mutation 
patients would be ideal candidates for cardiac myo-
sin inhibitors such as mavacamten. Strenuous exercise 
should be routinely discouraged, especially in patients 
with the MYH7 gene mutation.
Our data also suggest and confrm already established 
management paradigms—an individualized approach 
concerning specifc underlying clinical conditions and 
pathways (sudden cardiac death risk, heart failure, and 
atrial fbrillation). Such an approach has been proven to 
provide the opportunity to aggressively alter the progres-
sion of the disease, prevent mortality, and provide normal 
or extended life expectancy associated with improved 
quality of life. 
Study limitations 
We acknowledge that the large number of operators 
involved in echocardiographic measurements in this 
multicenter study represents an unavoidable limitation. 
However, care was taken to standardize measurements 
of cardiac dimension and function by prospectively pro-
viding detailed technical instructions to all participating 
centers. 
Finally, although the number of included patients in the 
study is modest, we believe that patient heterogenicity 
(multicenter study) confers substantial power to our data. 
Nevertheless, the modest size is one reason to exercise 
caution in extrapolating these results to the broad spec-
trum of hypertrophic cardiomyopathy.
A cross-sectional study design does not allow monitor-
ing of disease progression. However, disease progression 
and response to pharmacological and lifestyle interven-
tion in HCM is subject to our separate ongoing longitudi-
nal SILICOFCM study [14, 40]. 
Conclusions 
Up to this point, numerous mutations leading to HCM 
have been identifed and various clinical manifesta-
tions and phenotypic expressions of HCM have been 
described (from a completely asymptomatic condition, 
through outfow tract obstruction, diastolic dysfunction, 
to progressive heart failure and sudden cardiac death). 
However, no consistent association between the HCM 
genotype and phenotype have been identifed.
In those terms, our study is no exception. Although we 
focused our attention on the two most common sarco-
meric gene mutations responsible for HCM—MYBPC3 
and MYH7 gene mutations—we were not able to dem-
onstrate any substantial diferences regarding clinical and 
echocardiography fndings. More frequent systolic ante-
rior motion and other mitral valve abnormalities as well 
as increased left ventricle flling pressure in MYH7 gene 
mutation suggests that MYH7 gene mutation does pre-
sent with a more severe disease phenotype.
Correlation between the genetic and clinical status of 
HCM patients remains elusive in most of the cases—lim-
itation with a major impact on the development of per-
sonalized medicine approaches. Our study might subtly 
add to the overall understanding of such complex rela-
tions and might push genetic testing results from strictly 
diagnostic to prognostic fashion. 
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